These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3758052)

  • 21. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents.
    McNulty CA; Dent J; Wise R
    Antimicrob Agents Chemother; 1985 Dec; 28(6):837-8. PubMed ID: 2935076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bactericidal effect of combinations of nalidixic acid and various antibiotics on Enterobacteriaceae.
    Michel J; Luboshitzky R; Sacks T
    Antimicrob Agents Chemother; 1973 Sep; 4(3):201-4. PubMed ID: 4758830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae.
    Ruiz J; Gómez J; Navia MM; Ribera A; Sierra JM; Marco F; Mensa J; Vila J
    Diagn Microbiol Infect Dis; 2002 Apr; 42(4):257-61. PubMed ID: 12007443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of gentamicin, dibekacin, netilmicin and amikacin with various penicillins, cephalosporins, minocycline and new fluoro-quinolones against Enterobacteriaceae and Pseudomonas aeruginosa.
    Van der Auwera P
    J Antimicrob Chemother; 1985 Nov; 16(5):581-7. PubMed ID: 3935637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1984 Apr; 13(4):325-31. PubMed ID: 6233249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of the antimicrobial activity of pefloxacin (1589 RB), nalidixic acid and flumequin (author's transl)].
    Thabaut A; Durosoir JL
    Pathol Biol (Paris); 1982 Jun; 30(6):394-7. PubMed ID: 6810283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
    Biedenbach DJ; Toleman M; Walsh TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):13-21. PubMed ID: 16290025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992-98.
    Robert J; Cambau E; Grenet K; Trystram D; Péan Y; Fiévet MH; Jarlier V
    Clin Microbiol Infect; 2001 Oct; 7(10):553-61. PubMed ID: 11683796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of the newer quinolones compared with the classic ones and tobramycin.
    Boquet Jiménez E; Dalet Escribá F; Caballé L
    Infection; 1985; 13(4):193-6. PubMed ID: 2931382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nalidixic acid resistance in Salmonella strains with decreased susceptibility to ciprofloxacin isolated from humans in Turkey.
    Ercis S; Erdem B; Hasçelik G; Gür D
    Jpn J Infect Dis; 2006 Apr; 59(2):117-9. PubMed ID: 16632912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibacterial susceptibility testing by the dip-slide technique: a methodological evaluation.
    Dornbusch K; Nord CE; Olsson B; Thunell S
    Chemotherapy; 1976; 22(3-4):190-202. PubMed ID: 1269289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mode of action of 4-quinolones and possible mechanisms of resistance.
    Smith JT
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():21-9. PubMed ID: 3542946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro antibacterial activity of irloxacin (E-3432) on clinical isolates.
    Coll R; Esteve M; Moros M; Xicota MA; Parés J
    Drugs Exp Clin Res; 1987; 13(2):75-7. PubMed ID: 3582134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Susceptibility of multiply antibiotic-resistant pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin, and novobiocin.
    Gombert ME; Aulicino TM
    Antimicrob Agents Chemother; 1984 Dec; 26(6):933-4. PubMed ID: 6570085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Susceptibility of Enterobacter aerogenes and Enterobacter cloacae to 19 antimicrobial agents in vitro.
    Toala P; Lee YH; Wilcox C; Finland M
    Am J Med Sci; 1970 Jul; 260(1):41-55. PubMed ID: 4318051
    [No Abstract]   [Full Text] [Related]  

  • 36. Population analysis of susceptibility to ciprofloxacin and nalidixic acid in Staphylococcus, Pseudomonas aeruginosa, and Enterobacteriaceae.
    Søgaard P; Gahrn-Hansen B
    Acta Pathol Microbiol Immunol Scand B; 1986 Oct; 94(5):351-6. PubMed ID: 3098043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A study of the in vitro sensitivity of Enterobacteriaceae and Pseudomonas aeruginosa to 7 antimicrobial agents].
    Lynch MB; Mimica I; Valenzuela MC; Vilches A; Abarca S
    Rev Med Chil; 1972 Jan; 100(1):14-5. PubMed ID: 4622217
    [No Abstract]   [Full Text] [Related]  

  • 38. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
    Clarke AM; Zemcov SJ; Campbell ME
    J Antimicrob Chemother; 1985 Jan; 15(1):39-44. PubMed ID: 3156112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid.
    King A; Shannon K; Slegg J; Phillips I
    J Antimicrob Chemother; 1986 Aug; 18(2):163-9. PubMed ID: 3463557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-vitro activity of pefloxacin compared with six other quinolones.
    Ligtvoet EE; Wickerhoff-Minoggio T
    J Antimicrob Chemother; 1985 Oct; 16(4):485-90. PubMed ID: 3864776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.